NYSE American - Delayed Quote USD

NeurAxis, Inc. (NRXS)

2.2660

-0.0340

(-1.48%)

At close: May 14 at 3:59:53 PM EDT

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

Conference call will be held today, Monday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared

GlobeNewswire 2 days ago

NRXS
-1.48%
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its first quarter 2025, for the period ended March 31, 2025, on Monday, May 12, 2025, before marke

GlobeNewswire 9 days ago

NRXS
-1.48%
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis

Amazon, Johnson & Johnson, Cisco Systems and NeurAxis are included in this Analyst Blog.

Zacks 14 days ago

JNJ

CSCO

AMZN
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).

Zacks 14 days ago

JNJ

CSCO

AMZN
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

CARMEL, Ind., April 15, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 11:00 AM EST. Brian Carico, CEO of NeurAxis will be hosting the presentation and answeri

GlobeNewswire 29 days ago

NRXS
-1.48%
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth

NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.

Zacks last month

NRXS
-1.48%

^GSPC
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

Conference call will be held today, Thursday, March 20 at 9:00 am ETCARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024. 4Q24 Financial highlights Revenues increased 43% to $761 thousand in 4Q

GlobeNewswire last month

NRXS
-1.48%
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025

CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2024, for the period ended December 31, 2024, on Thursday, March 20, 2025, before market open. The Company has scheduled a conference call for the same day, Thu

GlobeNewswire 2 months ago

NRXS
-1.48%
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states. NeurAxis’ PENFS technology, IB-Stim, is FDA-cleared for f

GlobeNewswire 3 months ago

NRXS
-1.48%
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states. NeurAxis’ PENFS tec

GlobeNewswire 3 months ago

NRXS
-1.48%
NeurAxis Inc. Issues Letter to Shareholders

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico has published a letter to shareholders highlighting the Company’s achievements in 2024 and vision for 2025. Dear shareholders, We are thrilled to connect with you as we celebrate NeurAxis’s remarkable a

GlobeNewswire 3 months ago

NRXS
-1.48%
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced preliminary, unaudited revenues for the three and twelve months ended December 31, 2024. Revenues for 4Q24 wer

GlobeNewswire 4 months ago

NRXS
-1.48%
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The company presentation will take place

GlobeNewswire 4 months ago

NRXS
-1.48%
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software. NeurAxis Inc. will begin the process of commercially marketing RED and expects initial revenues in 1Q25 as there is a Category I CPT code assigned to the procedure and the procedure is covered by Medicare and most commercial insurance companies. CARMEL, Ind., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or t

GlobeNewswire 5 months ago

NRXS
-1.48%
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage

NRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market.

Zacks 5 months ago

NRXS
-1.48%

^GSPC
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

Conference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2024. 3Q24 Financial Highlights Revenues increased 40% to $667 thousand in the three months ended Septemb

GlobeNewswire 5 months ago

NRXS
-1.48%
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024

CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2024, on Tuesday, November 12, 2024, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 12, 2024, at 9

GlobeNewswire 6 months ago

NRXS
-1.48%
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market

Clearance expands indication for use from 11-18 year olds to 8-21 year olds; and from 3 devices, not to exceed 4 weeks, to 1 device per week for 4 weeksCARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it received a new 510(k) clearance for IB-Stim™ Nonimplanted Nerve S

GlobeNewswire 6 months ago

NRXS
-1.48%
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024

CARMEL, Ind., Oct. 29, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Capital Blue Cross Medical Members, effective October 1, 2024. Capital Blue Cross serves a 21-county region in Central Pennsylvania and

GlobeNewswire 6 months ago

NRXS
-1.48%
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation

CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, announced that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures effective January 1, 2026. NeurAxis’ PENF

GlobeNewswire 6 months ago

NRXS
-1.48%

Performance Overview

Return	NRXS	S&P 500 (^GSPC)
YTD	-3.57%	+0.19%
1-Year	-19.65%	+12.31%
3-Year	-64.03%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NeurAxis, Inc. (NRXS)

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis

Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth

NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025

UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

NeurAxis Inc. Issues Letter to Shareholders

NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024

NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market

NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024

NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation

Performance Overview